Blended Capital Needed to Unlock Pediatric Cancer Drug Development

South Africa’s drugmakers and the health department are at odds over lowest-price tenders. Pharmisa says cheaper imports have cost more than 2,500 jobs and eroded local manufacturing capacity.

The NICE Decision Support Unit and EEPRU have released updated Stata, Excel and R commands for mapping EQ-5D-3L data to the new EQ-5D-5L value set, giving UK HTA analysts a validated route to convert legacy three-level utility data ahead of NICE’s adoption of the five-level value set.

Why has Portugal’s Ordem dos Médicos welcomed the SINACC postponement?

The medical association says the surgery access system was still in testing and lacked safeguards, warning that reclassifying minor surgery could hide patients from waiting lists.

Read what 278,394 patients on the list means for the rollout.

#SyenzaNews #HealthEconomics #digitalhealth #healthcarepolicy

How are cell therapies redefining cancer care through rigorous HTA evaluation?

INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness.

Explore the full breakdown and its implications for global cancer treatment.
#SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

💊 Is it safe to stop statins in elderly patients for primary prevention?

A recent trial shows that deprescribing statins in older adults without established cardiovascular disease does not increase the risk of adverse outcomes, supporting more individualized prescribing decisions.

Discover the full trial results and implications for clinical practice.

#SyenzaNews #clinicaltrials #pharmaceuticals #costeffectiveness #healthcarepolicy

Is the US childhood vaccine schedule really out of step with peer nations?

A new analysis finds it aligns closely with other developed countries in both the number and timing of recommended vaccines.

Explore the full comparison and what it means for vaccine policy.
#SyenzaNews #globalhealth #HealthcareInnovation #healthcarepolicy #innovation

How can real-world data networks improve safety evaluations for multiple sclerosis therapies?

A new collaborative MS data initiative is enabling more robust assessments of treatment safety by pooling patient insights across sources.

Discover how this approach is advancing evidence generation in neurology.
#SyenzaNews #digitalhealth #clinicaltrials #datascience #innovation

💰 Is pembrolizumab delivering high value for HNSCC in Switzerland?

A new analysis confirms the immunotherapy offers strong cost-effectiveness, supporting smarter resource allocation and improved patient outcomes in oncology.

Explore the full economic evaluation and its implications for market access.

#SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

Is tirzepatide delivering better value than semaglutide for patients and payers?

A fresh analysis shows how tirzepatide can drive greater cost savings alongside improved health outcomes in obesity and type 2 diabetes management.

Discover the key findings shaping treatment and reimbursement decisions.

#SyenzaNews #pharmaceuticals #HealthEconomics #costeffectiveness

🚀 What if the first oral GLP-1 therapy just cleared its biggest regulatory hurdle in Europe?

The MHRA has approved orforglipron, delivering the continent’s first oral win and offering patients a convenient, needle-free option for weight management and type 2 diabetes.

Read the full story on this landmark approval.
#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess